Towa Pharmaceutical Co., Ltd. (FRA:6QC)

Market Cap	1.12B +27.4%
Revenue (ttm)	1.47B +6.5%
Net Income	116.49M +11.2%
EPS	2.37 +11.2%
Shares Out	n/a
PE Ratio	9.65
Forward PE	n/a
Dividend	0.47 (2.12%)
Ex-Dividend Date	Sep 29, 2025

Volume	n/a
Average Volume	n/a
Open	22.40
Previous Close	22.20
Day's Range	22.40 - 22.40
52-Week Range	14.00 - 23.60
Beta	n/a
RSI	55.88
Earnings Date	May 14, 2026

About Towa Pharmaceutical

Towa Pharmaceutical Co., Ltd., together with its subsidiaries, manufactures and sale ethical drugs in Japan. It operates through two segments; Domestic and Overseas. The company provides its products in the therapeutic areas of digestive system, nervous system, and allergic diseases, as well as vitamins, antibiotics, and oncology products, as well as provide formulations from Tablets, Capsules, Injectable, Patches, eye drops, and other products. It also offers IT service related to healthcare; disease risk testing services; and quasi drugs. In ...

• Industry: Pharmaceutical Preparations
• Founded: 1951
• Employees: 4,788
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: 6QC

Financial Performance

In fiscal year 2025, Towa Pharmaceutical's revenue was 259.59 billion, an increase of 13.89% compared to the previous year's 227.93 billion. Earnings were 18.99 billion, an increase of 17.39%.

Financial numbers in JPY